Becton, Dickinson and Company (NYSE:BDX) Given Average Rating of “Hold” by Analysts

Becton, Dickinson and Company (NYSE:BDX) has been given an average rating of “Hold” by the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $213.30.

BDX has been the topic of several research analyst reports. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Barclays lowered their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd.

Becton, Dickinson and Company Stock Down 0.6%

NYSE:BDX opened at $187.27 on Monday. The company has a market capitalization of $53.68 billion, a price-to-earnings ratio of 33.68, a price-to-earnings-growth ratio of 1.52 and a beta of 0.27. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The stock has a 50-day simple moving average of $187.65 and a 200 day simple moving average of $190.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,965 shares of company stock worth $551,536. Corporate insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Hara Capital LLC lifted its position in Becton, Dickinson and Company by 26.4% during the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier’s stock worth $76,000 after acquiring an additional 70 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Becton, Dickinson and Company by 3.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,701 shares of the medical instruments supplier’s stock worth $5,377,000 after acquiring an additional 861 shares during the last quarter. Quantinno Capital Management LP lifted its position in Becton, Dickinson and Company by 35.8% during the 4th quarter. Quantinno Capital Management LP now owns 10,442 shares of the medical instruments supplier’s stock worth $2,369,000 after acquiring an additional 2,752 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its position in Becton, Dickinson and Company by 11.8% during the 4th quarter. Rafferty Asset Management LLC now owns 32,777 shares of the medical instruments supplier’s stock worth $7,436,000 after acquiring an additional 3,461 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.